IRVINE, Calif., Aug. 25 -- Legendary American tribe singer
Arlo Guthrie is place to perform at the Orange County Great Park on Saturday
August 30th at 8:00 p.m. as part of the Great Park Night Flight Concert
Series. Attendance and parking are release to the public.
Arlo is best known for his epic musical soliloquy Alice's Restaurant.
Three generations of Guthrie's will perform at the Great Park, Arlo, his
son Abe, and grandson Krishna. They will highlight the performance with a
drink to Arlo's father, Woody Guthrie, by singing the long time favorite
"This Land Is Your Land".
In 2006 Arlo, Abe and Krishna staged the "Boy's Night Out" tour across
Europe, and at present this go comes to America for nine shows only. The Orange
County Great Park is the only when California performance.
Over the past 20 years, Arlo's son Abe has performed keyboard
concomitant and powerful supporting vocals along with his dad. It was
rare to see an Arlo show without Abe at his side. Arlo, who has just
completed a yearlong Solo Reunion Tour, aforementioned, "Abe is just a great
player. I can't wait to get back to playing together." Krishna Guthrie,
at only seventeen, is already an accomplished musician playing drums and
guitar. He got his beginning drum congeal at deuce; by trio he had already made his
first-class honours degree appearance with his father and grandad on level. Since and so, he
has occasionally joined the menage on point playing drums.
Arlo Guthrie was innate with a guitar in one hand and a harmonica in the
other in Coney Island, Brooklyn, New York in 1947. He is the firstborn son of
America's most beloved singer/writer/philosopher, Woody Guthrie, and
Marjorie Mazia Guthrie. His mother was a professional social dancer with the
Martha Graham Company and founder of The Committee to Combat Huntington's
Disease.
Arlo gave his first base public public presentation at historic period 13 and quickly became
involved in the music that was shaping the world during the 1960s. Arlo
practically lived in the most famous venues of the "Folk Boom" eRA. In New
York City he hung extinct at Gerdes Folk City, The Gaslight and The Bitter End.
In Boston it was Club 47 and in Philadelphia he made places like The 2nd
Fret and The Main Point his household.
Arlo Guthrie's career exploded in 1967 with the release of his album,
Alice's Restaurant, whose title song premiered at the Newport Folk Festival
and helped foster a new commitment to social consciousness and activism
among the '60s generation. Arlo went on to star in the 1969 Hollywood cinema
version of Alice's Restaurant, directed by Arthur Penn.
Though Arlo's definitive interpretation of Steve Goodman's "City of New
Orleans" may get been his only "hit" song in the traditional sense, he has
ne'er the less achieved international stature. The 18 minute "Alice's
Restaurant," spell too long for radio airplay, has become an American
classic.
Over the last-place four decades Arlo has toured end-to-end North America,
Europe, Africa, Asia and Australia winning a broad and dedicated following.
In addition to being an accomplished musician -- playing the piano, six and
twelve-string guitar, harmonica and a xII other instruments -- Arlo is a
natural-born teller whose screaming tales and anecdotes ar woven
seamlessly into his performances.
The Orange County Great Park, which is almost twice the size of it of New
York City's Central Park, testament be a major metropolitan park and the focal
point of the overhaul of the 4,700-acre former Marine Corps Air
Station at El Toro. The Great Park will let in extensive natural areas and
open space in add-on to recreational and cultural uses.
For more information, please go to http://www.ocgp.org.
More info
Friday, 29 August 2008
Tuesday, 19 August 2008
Medarex Announces Initiation Of Phase 2 Clinical Development Program For The Treatment Of Lupus
�Medarex, Inc.
(Nasdaq: MEDX) announced that its collaborator MedImmune, Inc. has
initiated a Phase 2A multi-dose clinical test of MEDI-545 for the
potential handling of systemic lupus erythematosus (SLE or lupus).
MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human
Antibody Development System(R). Under the footing of the agreement, Medarex
will welcome a milestone payment of an undisclosed amount.
The Phase 2A clinical visitation is intentional to appraise the guard and
tolerability of multiple subcutaneous loony toons schedules of MEDI-545 or placebo
in adult patients with control to austere active lupus. The study will also
assess the effects of MEDI-545 on disease activity in lupus patients. This
randomized, double blind, placebo-controlled run is expected to enrol 80
patients and testament be conducted at 20 sites in the United States.
MedImmune is as well conducting a Phase 1 clinical trial for MEDI-545 in
idiopathic inflammatory myositis, an immunologic disease that involves
chronic muscle fervour, pain and weakness.
"Data from an earlier reported placebo-controlled Phase 1 study
suggested curative activity with single doses in patients with lupus and
demonstrated an acceptable safety profile," said Geoffrey M. Nichol,
M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are
selfsame excited about the office of the interferon alpha inflammatory tract
and front forward to exploring its potential in treating patients with lupus
and other autoimmune diseases."
About MEDI-545
MEDI-545 (previously known as MDX-1103) is a fully human monoclonal
antibody targeting interferon-alpha. Published data indicate that levels of
interferon-alpha ar elevated in many patients with active SLE and other
autoimmune disorders, and may be associated with disease activity.
Preclinical information from creature models suggest that MEDI-545 may suppress the
abnormal immune activity associated with lupus by binding to multiple
interferon-alpha subtypes seen in the serum of lupus patients.
In November 2004, MedImmune entered into a collaborationism with Medarex
to focal point on two specific antibodies, one of which was MDX-1103 (now known
as MEDI-545). Under the footing of the agreement, MedImmune is responsible
for all ongoing clinical development activities. Prior to the root of
polar studies, Medarex may elect to co-develop the products in refund for
the opportunity to co-promote and to welcome a portion of the commercial
winnings in the United States. In all other cases, Medarex will be entitled
to have milestone payments and royalties.
About Lupus
Approximately 350,000 individuals in the United States are affected
with lupus, a chronic rabble-rousing disease that causes the body to attack
its own tissues and organs, including the skin, joints, blood and kidneys.
Treatments for lupus include anti-inflammatory drug drugs, antimalarials,
corticosteroids and drugs approved for other purposes, such as
immunosuppressive drug agents minded to cancer patients undergoing chemotherapy
or medicines developed to regale arthritis patients. Lupus occurs about 10
times more frequently in adult females than grownup males, and is two to
iII times more common among African Americans, Hispanics, Asians and
Native Americans.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
malignant neoplastic disease, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product evolution and clinical
manufacturing go through to sire, support and potentially commercialise
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex applied science are in human clinical testing or have had INDs submitted
for such trials, with seven of the almost advanced mathematical product candidates
currently in Phase 3 clinical trials or the subject of regulative
applications for marketing sanction. Medarex is committed to building
value by development a various pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Statement on Cautionary Factors
Except for the
(Nasdaq: MEDX) announced that its collaborator MedImmune, Inc. has
initiated a Phase 2A multi-dose clinical test of MEDI-545 for the
potential handling of systemic lupus erythematosus (SLE or lupus).
MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human
Antibody Development System(R). Under the footing of the agreement, Medarex
will welcome a milestone payment of an undisclosed amount.
The Phase 2A clinical visitation is intentional to appraise the guard and
tolerability of multiple subcutaneous loony toons schedules of MEDI-545 or placebo
in adult patients with control to austere active lupus. The study will also
assess the effects of MEDI-545 on disease activity in lupus patients. This
randomized, double blind, placebo-controlled run is expected to enrol 80
patients and testament be conducted at 20 sites in the United States.
MedImmune is as well conducting a Phase 1 clinical trial for MEDI-545 in
idiopathic inflammatory myositis, an immunologic disease that involves
chronic muscle fervour, pain and weakness.
"Data from an earlier reported placebo-controlled Phase 1 study
suggested curative activity with single doses in patients with lupus and
demonstrated an acceptable safety profile," said Geoffrey M. Nichol,
M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are
selfsame excited about the office of the interferon alpha inflammatory tract
and front forward to exploring its potential in treating patients with lupus
and other autoimmune diseases."
About MEDI-545
MEDI-545 (previously known as MDX-1103) is a fully human monoclonal
antibody targeting interferon-alpha. Published data indicate that levels of
interferon-alpha ar elevated in many patients with active SLE and other
autoimmune disorders, and may be associated with disease activity.
Preclinical information from creature models suggest that MEDI-545 may suppress the
abnormal immune activity associated with lupus by binding to multiple
interferon-alpha subtypes seen in the serum of lupus patients.
In November 2004, MedImmune entered into a collaborationism with Medarex
to focal point on two specific antibodies, one of which was MDX-1103 (now known
as MEDI-545). Under the footing of the agreement, MedImmune is responsible
for all ongoing clinical development activities. Prior to the root of
polar studies, Medarex may elect to co-develop the products in refund for
the opportunity to co-promote and to welcome a portion of the commercial
winnings in the United States. In all other cases, Medarex will be entitled
to have milestone payments and royalties.
About Lupus
Approximately 350,000 individuals in the United States are affected
with lupus, a chronic rabble-rousing disease that causes the body to attack
its own tissues and organs, including the skin, joints, blood and kidneys.
Treatments for lupus include anti-inflammatory drug drugs, antimalarials,
corticosteroids and drugs approved for other purposes, such as
immunosuppressive drug agents minded to cancer patients undergoing chemotherapy
or medicines developed to regale arthritis patients. Lupus occurs about 10
times more frequently in adult females than grownup males, and is two to
iII times more common among African Americans, Hispanics, Asians and
Native Americans.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
malignant neoplastic disease, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product evolution and clinical
manufacturing go through to sire, support and potentially commercialise
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex applied science are in human clinical testing or have had INDs submitted
for such trials, with seven of the almost advanced mathematical product candidates
currently in Phase 3 clinical trials or the subject of regulative
applications for marketing sanction. Medarex is committed to building
value by development a various pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Statement on Cautionary Factors
Except for the
Saturday, 9 August 2008
Rob Essers
Artist: Rob Essers
Genre(s):
New Age
Electronic: Progressive
Discography:
Raincolors
Year: 2002
Tracks: 14
A Lizards Walk
Year: 1997
Tracks: 3
FDA Clears The Pathwork(R) Tissue Of Origin Test For Hard To Identify Tumors
Subscribe to:
Posts (Atom)